UA68324C2 - Dimers of "cloverleaf" peptide (variants), method for their production (variants) and pharmaceutical composition (variants) - Google Patents

Dimers of "cloverleaf" peptide (variants), method for their production (variants) and pharmaceutical composition (variants) Download PDF

Info

Publication number: UA68324C2
Authority: UA; Ukraine
Prior art keywords: peptide; clover; fact; monomers; ite
Prior art date: 1994-08-26

Application number

UA97020840A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-26

Filing date

1995-08-25

Publication date

2004-08-16

1995-08-25 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2004-08-16 Publication of UA68324C2 publication Critical patent/UA68324C2/uk

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 121
239000000539 dimer Substances 0.000 title claims abstract description 43
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
238000004519 manufacturing process Methods 0.000 title claims abstract description 4
238000000034 method Methods 0.000 title claims description 22
239000000178 monomer Substances 0.000 claims abstract description 43
206010006187 Breast cancer Diseases 0.000 claims abstract description 5
208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 3
241000219793 Trifolium Species 0.000 claims description 77
108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 8
238000004587 chromatography analysis Methods 0.000 claims description 7
230000000968 intestinal effect Effects 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
238000002955 isolation Methods 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
238000000605 extraction Methods 0.000 claims 2
235000011449 Rosa Nutrition 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 abstract description 32
210000004027 cell Anatomy 0.000 description 39
108010076504 Protein Sorting Signals Proteins 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 25
239000013598 vector Substances 0.000 description 21
235000009991 pite Nutrition 0.000 description 18
244000293655 pite Species 0.000 description 18
240000004808 Saccharomyces cerevisiae Species 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 17
229940024606 amino acid Drugs 0.000 description 16
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
150000001413 amino acids Chemical class 0.000 description 14
238000000746 purification Methods 0.000 description 14
108020004414 DNA Proteins 0.000 description 12
239000013612 plasmid Substances 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 11
239000002609 medium Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 11
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000004382 Amylase Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
238000000855 fermentation Methods 0.000 description 9
230000004151 fermentation Effects 0.000 description 9
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
235000019253 formic acid Nutrition 0.000 description 8
238000005119 centrifugation Methods 0.000 description 7
210000001035 gastrointestinal tract Anatomy 0.000 description 7
238000004949 mass spectrometry Methods 0.000 description 7
210000004400 mucous membrane Anatomy 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
239000000523 sample Substances 0.000 description 7
230000003248 secreting effect Effects 0.000 description 7
210000005253 yeast cell Anatomy 0.000 description 7
241000233866 Fungi Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
241001190694 Muda Species 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000000945 filler Substances 0.000 description 5
230000010076 replication Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
241000238631 Hexapoda Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
102000015728 Mucins Human genes 0.000 description 4
108010063954 Mucins Proteins 0.000 description 4
101100260017 Mus musculus Tbx19 gene Proteins 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000003550 marker Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 3
102100022624 Glucoamylase Human genes 0.000 description 3
101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 3
102000004882 Lipase Human genes 0.000 description 3
108090001060 Lipase Proteins 0.000 description 3
239000004367 Lipase Substances 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
101100425749 Mus musculus Tnfrsf18 gene Proteins 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
101150106031 TRI gene Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000035876 healing Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
235000019421 lipase Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000009466 transformation Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
102000013142 Amylases Human genes 0.000 description 2
108010065511 Amylases Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019418 amylase Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000005081 epithelial layer Anatomy 0.000 description 2
239000008103 glucose Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000010354 integration Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
101800002326 Adipokinetic hormone Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000269350 Anura Species 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102000035101 Aspartic proteases Human genes 0.000 description 1
108091005502 Aspartic proteases Proteins 0.000 description 1
108091005658 Basic proteases Proteins 0.000 description 1
241001211977 Bida Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
241001049165 Caria Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
241000632511 Daviesia arborea Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101001084276 Homo sapiens Phosphotriesterase-related protein Proteins 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241001135569 Human adenovirus 5 Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108700001097 Insect Genes Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
102220579591 Mitogen-activated protein kinase 3_I86Y_mutation Human genes 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
241001387976 Pera Species 0.000 description 1
102100030961 Phosphotriesterase-related protein Human genes 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
235000011684 Sorghum saccharatum Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
235000009430 Thespesia populnea Nutrition 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010088411 Trefoil Factor-2 Proteins 0.000 description 1
102100039172 Trefoil factor 2 Human genes 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
108010048241 acetamidase Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
-1 aromatic amino acids Chemical class 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
102000053695 human GPR180 Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
101150023613 mev-1 gene Proteins 0.000 description 1
229940051875 mucins Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
150000002482 oligosaccharides Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000004262 preparative liquid chromatography Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical class OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
101150039622 so gene Proteins 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
108010013137 spasmolytic polypeptide Proteins 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

UA97020840A 1994-08-26 1995-08-25 Dimers of "cloverleaf" peptide (variants), method for their production (variants) and pharmaceutical composition (variants) UA68324C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK98394		1994-08-26
PCT/DK1995/000343 WO1996006861A1 (en)	1994-08-26	1995-08-25	Trefoil peptide dimer

Publications (1)

Publication Number	Publication Date
UA68324C2 true UA68324C2 (en)	2004-08-16

Family

ID=8099704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97020840A UA68324C2 (en)	1994-08-26	1995-08-25	Dimers of "cloverleaf" peptide (variants), method for their production (variants) and pharmaceutical composition (variants)

Country Status (21)

Country	Link
EP (2)	EP0777687B1 (pl)
JP (3)	JPH10504720A (pl)
KR (1)	KR100255911B1 (pl)
CN (1)	CN1070867C (pl)
AT (1)	ATE329929T1 (pl)
AU (1)	AU694796B2 (pl)
BR (1)	BR9508773A (pl)
CA (1)	CA2196876C (pl)
CZ (2)	CZ289705B6 (pl)
DE (1)	DE69535060T2 (pl)
DK (1)	DK0777687T3 (pl)
ES (1)	ES2267104T3 (pl)
FI (1)	FI119989B (pl)
HU (1)	HU226921B1 (pl)
MX (1)	MX9701239A (pl)
NO (1)	NO323642B1 (pl)
PL (1)	PL184516B1 (pl)
PT (1)	PT777687E (pl)
RU (1)	RU2162857C2 (pl)
UA (1)	UA68324C2 (pl)
WO (1)	WO1996006861A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6221840B1 (en) *	1991-02-14	2001-04-24	The General Hospital Corporation	Intestinal trefoil proteins
US6063755A (en)	1991-02-14	2000-05-16	The General Hospital Corporation	Intestinal trefoil proteins
US6337195B1 (en)	1995-06-06	2002-01-08	Human Genome Sciences, Inc.	Colon specific genes and proteins
US6525018B1 (en)	1999-05-17	2003-02-25	The General Hospital Corp.	Treating eye disorders using intestinal trefoil proteins
WO1999010377A1 (en)	1997-08-25	1999-03-04	The General Hospital Corporation	Receptor for intestinal trefoil factor
EP1292675A2 (en) *	2000-05-26	2003-03-19	Diadexus, Inc.	Method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1341817A2 (en) *	2000-12-08	2003-09-10	Novo Nordisk A/S	Tff peptides
US7538082B2 (en)	2001-04-24	2009-05-26	The General Hospital Corporation	Methods and compositions for treating oral and esophageal lesions
EP1842858A3 (en) *	2001-04-24	2008-04-02	The General Hospital Corporation	Methods and compositions for treating oral and esophageal lesions
MXPA03009772A (es) *	2001-04-24	2004-02-23	Gen Hospital Corp	Metodos y composiciones para tratar lesiones orales y del esofago.
EP1401481A1 (en) *	2001-06-14	2004-03-31	Novo Nordisk A/S	Mucosal repair by tff dimer peptides
RU2224797C2 (ru) *	2002-04-04	2004-02-27	Эльдаров Михаил Анатольевич	Рекомбинантная плазмидная днк pacyclans для переноса и экспрессии в клетках escherichia coli гена l-аспарагиназы erwinia carotovora (ecar-lans) и способ получения рекомбинантной ecar-lans из биомассы штамма e.coli-продуцента
WO2003068817A1 (en) *	2002-02-11	2003-08-21	Novo Nordisk A/S	Management of mucosal viscosity by tff monomer peptides
AU2003224773B2 (en) *	2002-03-26	2010-08-26	The General Hospital Corporation	Combination therapy using trefoil peptides
ES2642214T3 (es)	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
CN103096917A (zh)	2010-06-04	2013-05-08	三叶草私人有限公司	用于治疗慢性肺病的三叶因子（tff）
CN102526702A (zh) *	2010-12-23	2012-07-04	中国医学科学院基础医学研究所	小肽tff3治疗代谢综合征的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO884054D0 (no) *	1988-09-13	1988-09-13	Bio Tech As	Nytt pentapeptid og fremgangsmaate for fremstilling derav.
DE69232619T2 (de) *	1991-02-14	2002-09-12	The General Hospital Corp., Charlestown	Intestinale kleeblatt-proteine

1995
- 1995-08-25 CA CA002196876A patent/CA2196876C/en not_active Expired - Fee Related
- 1995-08-25 CN CN95194798A patent/CN1070867C/zh not_active Expired - Fee Related
- 1995-08-25 RU RU97104484/13A patent/RU2162857C2/ru not_active IP Right Cessation
- 1995-08-25 PT PT95929783T patent/PT777687E/pt unknown
- 1995-08-25 AU AU33415/95A patent/AU694796B2/en not_active Ceased
- 1995-08-25 AT AT95929783T patent/ATE329929T1/de active
- 1995-08-25 DE DE69535060T patent/DE69535060T2/de not_active Expired - Lifetime
- 1995-08-25 ES ES95929783T patent/ES2267104T3/es not_active Expired - Lifetime
- 1995-08-25 JP JP8508422A patent/JPH10504720A/ja not_active Ceased
- 1995-08-25 CZ CZ1997548A patent/CZ289705B6/cs not_active IP Right Cessation
- 1995-08-25 KR KR1019970700968A patent/KR100255911B1/ko not_active Expired - Fee Related
- 1995-08-25 BR BR9508773A patent/BR9508773A/pt not_active IP Right Cessation
- 1995-08-25 MX MX9701239A patent/MX9701239A/es active IP Right Grant
- 1995-08-25 UA UA97020840A patent/UA68324C2/uk unknown
- 1995-08-25 PL PL95318785A patent/PL184516B1/pl not_active IP Right Cessation
- 1995-08-25 EP EP95929783A patent/EP0777687B1/en not_active Expired - Lifetime
- 1995-08-25 EP EP06115209A patent/EP1739091A1/en not_active Withdrawn
- 1995-08-25 WO PCT/DK1995/000343 patent/WO1996006861A1/en not_active Ceased
- 1995-08-25 DK DK95929783T patent/DK0777687T3/da active
- 1995-08-25 HU HU9801427A patent/HU226921B1/hu not_active IP Right Cessation
1997
- 1997-02-25 FI FI970783A patent/FI119989B/fi not_active IP Right Cessation
- 1997-02-25 NO NO19970844A patent/NO323642B1/no not_active IP Right Cessation
1999
- 1999-10-13 CZ CZ19993618A patent/CZ289864B6/cs not_active IP Right Cessation
2001
- 2001-11-28 JP JP2001363220A patent/JP4156829B2/ja not_active Expired - Fee Related
2006
- 2006-12-20 JP JP2006343522A patent/JP2007161720A/ja active Pending

Also Published As

Publication number	Publication date
EP0777687B1 (en)	2006-06-14
DE69535060D1 (de)	2006-07-27
NO970844D0 (no)	1997-02-25
CA2196876C (en)	2007-04-17
KR100255911B1 (ko)	2000-05-01
FI119989B (fi)	2009-05-29
JP2007161720A (ja)	2007-06-28
BR9508773A (pt)	1997-12-30
AU694796B2 (en)	1998-07-30
DK0777687T3 (da)	2006-10-16
HUT77917A (hu)	1998-10-28
PL184516B1 (pl)	2002-11-29
CN1070867C (zh)	2001-09-12
CZ289864B6 (cs)	2002-04-17
JP4156829B2 (ja)	2008-09-24
CZ289705B6 (cs)	2002-03-13
CZ54897A3 (en)	1997-08-13
NO970844L (no)	1997-04-28
EP1739091A1 (en)	2007-01-03
JPH10504720A (ja)	1998-05-12
FI970783A0 (fi)	1997-02-25
AU3341595A (en)	1996-03-22
ATE329929T1 (de)	2006-07-15
CA2196876A1 (en)	1996-03-07
WO1996006861A1 (en)	1996-03-07
JP2002191385A (ja)	2002-07-09
HU226921B1 (en)	2010-03-01
NO323642B1 (no)	2007-06-18
PL318785A1 (en)	1997-07-07
EP0777687A1 (en)	1997-06-11
DE69535060T2 (de)	2006-12-28
CN1156459A (zh)	1997-08-06
FI970783L (fi)	1997-02-25
PT777687E (pt)	2006-10-31
ES2267104T3 (es)	2007-03-01
RU2162857C2 (ru)	2001-02-10
MX9701239A (es)	1997-05-31

Publication	Publication Date	Title
UA68324C2 (en)	2004-08-16	Dimers of "cloverleaf" peptide (variants), method for their production (variants) and pharmaceutical composition (variants)
EP0293357B1 (fr)	1993-05-05	Expression de la proapolipoprotéine A-I humaine
UA70283C2 (en)	2004-10-15	Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants)
FI87800C (fi)	1993-02-25	Foerfarande foer framstaellning av glukagon i jaest
KR20150008870A (ko)	2015-01-23	락토페린 융합 단백질 및 그의 제조방법
WO2023227133A1 (zh)	2023-11-30	人胰淀素类似物、其衍生物及用途
CN113150172A (zh)	2021-07-23	Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
EP0362259B1 (en)	1996-03-06	Method of producing cystatin c or modifications hereof and dna-sequence for use when carrying out the method
Li et al.	2020	Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment
CN104693300B (zh)	2021-07-20	改良型聚乙二醇化重组人干扰素α2b
US10179802B2 (en)	2019-01-15	Conotoxin peptide κ-CPTX-BTL04, preparation method therefor, and uses thereof
US11980671B2 (en)	2024-05-14	Use of bacterial voltage gated ion channels for human therapies
CN106146667B (zh)	2020-06-19	一种Exendin-4融合蛋白及其制备方法与用途
US10246490B2 (en)	2019-04-02	Conotoxin peptide κ-CPTX-BTL02, preparation method therefor, and uses thereof
KR20180114684A (ko)	2018-10-19	신규한 Stx2e 에피토프 단백질 및 이를 포함하는 백신 조성물
JP5019442B2 (ja)	2012-09-05	心筋の収縮を抑制するグラモストラ・スパチュラタ由来のポリペプチドおよびその遺伝子。
US20180162909A1 (en)	2018-06-14	Conotoxin peptide k-cptx-btl03, preparation method therefor, and uses thereof
EP4606898A1 (en)	2025-08-27	Cell surface large-display technology using extracellular membrane lipoprotein prsa display system
EP3738978A1 (en)	2020-11-18	In-vivo release sustained recombinant coagulation factor viii and preparation method therefor
JP2002534960A (ja)	2002-10-22	ワクチン
KR970009354B1 (ko)	1997-06-10	모티린형 폴리펩티드 및 그 용도
CN111094357A (zh)	2020-05-01	一类新的Bcl10聚合抑制剂及其应用
CN119431515A (zh)	2025-02-14	一种穿膜蛋白及其应用
EP1602726A2 (en)	2005-12-07	Human tachykinin-related splice variants and compositions thereof
KR101752775B1 (ko)	2017-07-03	단백질의 재설계를 위한 허용 위치 선별 및 이를 이용한 변형된 단백질의 제조 방법